Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

August 16, 2022

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2024

Conditions
Non-proliferative Diabetic RetinopathyProliferative Diabetic Retinopathy
Interventions
DRUG

OPL-0401 Dose 1

Pharmaceutical Form: Capsule; Route of Administration: Oral

DRUG

Placebo

Pharmaceutical Form: Capsule; Route of Administration: Oral

Trial Locations (25)

21209

The Retina Care Center, Baltimore

27587

North Carolina Retina Associates, Wake Forest

29456

Charleston Neuroscience Institute, Ladson

32757

Mid Florida Eye Center, Mt. Dora

48439

Retina Associates of Michigan, Grand Blanc

71291

Eye Associates of Northeast Louisiana, West Monroe

75231

Texas Retina Associates, Dallas

77384

Retina Consultants of Texas, The Woodlands

78240

Medical Center Ophthalmology Associates, San Antonio

78503

Valley Retina Institute, PA, McAllen

78681

Austin Retina Associates - Round Rock, Round Rock

78705

Austin Retina Associates, Austin

78750

Austin Clinical Research, LLC, Austin

80528

Panorama Eye Care, LLC, Fort Collins

84107

Retina Associates of Utah, Salt Lake City

92503

Retina Consultants of Southern California, Riverside

92505

Southern California Permanente Medical Group, Riverside

93036

California Retina Consultants, Santa Barbara

94040

Northern California Retina Vitreous Associates, Mountain View

95825

Retinal Consultants Medical Group, Sacramento

98104

Pacific Northwest Retina, Seattle

99204

Spokane Eye Clinical Research, Spokane

02114

Massachussetts Eye and Ear, Boston

87102-3657

Vision Research Center Eye Associates of New Mexico, Albuquerque

79606-1224

Strategic Clinical Research Group LLC, Willow Park

All Listed Sponsors
lead

Valo Health, Inc.

INDUSTRY